cjc 1295 ipamorelin drug interactions CJC-1295 / Blend CJC-1295 No DAC + Ipamorelin

Higher IGF-1 levels are associated with both an increased and decreased risk of certain cancer types

Sermorelin activates only the GHRH pathway with no GHRP component

long-term epidemiological data absent Metabolic effects potential impacts on glucose metabolism, insulin sensitivity, and lipid profiles inadequately characterized in long-term studies Endocrine disruption effects on other hormonal axes with chronic use not well-studied Regulatory & Competitive Sport Status FDA Position Neither CJC-1295 nor Ipamorelin has received FDA approval for any human therapeutic indication: Investigational New Drug status available only for qualified research applications 2024 FDA compounding restrictions both peptides temporarily placed on Category 2 list (substances presenting significant safety risks), later removed pending further review Not approved for human use in any formulation or indication Warning letters issued to companies marketing peptides for human therapeutic use Compounding status uncertain as of 2024-2025, regulatory position on compounding pharmacy access remains in flux The FDA has specifically cited cardiovascular safety concerns, immunogenicity risks, and lack of adequate safety and efficacy data as bases for restricting access outside formal research contexts

Pairing a GHRH analog with a ghrelin mimetic is a recurring theme in the literature, and it is also why blended research compounds exist, such as the tesamorelin and ipamorelin blend studied as a single preparation

Inconsistent Administration: Variations in timing, route, or technique can introduce uncontrolled variables